Problematic variation in local institutional review of a multicenter genetic epidemiology study.

CONTEXT Sequencing of the human genome provides an immense resource for studies correlating DNA variation and epidemiology. However, appropriately powered genetic epidemiology studies often require recruitment from multiple sites. OBJECTIVES To document the burden imposed by review of multicenter studies and to determine the variability among local institutional review boards (IRBs) in the approval of a multicenter genetic epidemiology study. DESIGN A PubMed search was performed to determine the frequency of citations of multicenter studies by 5-year intervals from 1974 through 2002. A 7-question survey was sent to all participating study centers to obtain information on frequency of IRB meetings, dates for submission and approval, use/nonuse of a specific consent form, type of review performed, types of consent forms required, preparation time, and number of changes requested by the IRB at each center. Centers also provided a copy of all consent forms they generated and IRB correspondence regarding the study. SETTING AND PARTICIPANTS Thirty-one of 42 cystic fibrosis care centers in this single US multicenter genetic epidemiology study of cystic fibrosis replied, yielding a 74% response rate. MAIN OUTCOME MEASURES Frequency of published research studies and consistency among IRBs. RESULTS The number of all published single-center studies has increased 1.3-fold since 1985, while the number of published epidemiology and genetic epidemiology multicenter studies increased by 8- and 9-fold, respectively, during this same period. Evaluation of the risk of the same genetic epidemiology study by 31 IRBs ranged from minimal to high, resulting in 7 expedited reviews (23%) and 24 full reviews (77%). The number of consents required by the IRBs ranged from 1 to 4; 15 IRBs (48%) required 2 or more consents, while 10 (32%) did not require assent for children. The most common concern (52%) of IRBs pertained to the genetic aspects of the study. CONCLUSIONS Review of a protocol for a multicenter genetic epidemiology study by local IRBs was highly variable. Lack of uniformity in the review process creates uneven human subjects protection and incurs considerable inefficiency. The need for reform, such as the proposed centralized review, is underscored by the ever increasing rate of genetic discoveries facilitated by the Human Genome Project and the unprecedented opportunity to assess the relevance of genetic variation to public health.

[1]  J. Osborne,et al.  Responses of local research ethics committees to a study with approval from a multicentre research ethics committee , 2000, BMJ : British Medical Journal.

[2]  M V Olson,et al.  The human genome project. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[3]  K. Alberti Local research ethics committees , 1995, BMJ.

[4]  Michael F. Mangano Evaluation within the U.S. Department of Health and Human Services Office of Inspector General , 1990 .

[5]  R. Steinbrook Improving protection for research subjects. , 2002, The New England journal of medicine.

[6]  M. Radeos,et al.  Variation in institutional review board responses to a standard protocol for a multicenter clinical trial. , 2001, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[7]  Bandman El Protection of human subjects. , 1980, JAMA.

[8]  K. Jamrozik The case for a new system for oversight of research on human subjects , 2000, Journal of medical ethics.

[9]  M Gwinn,et al.  Informed consent for population-based research involving genetics. , 2001, JAMA.

[10]  H. Boonstra,et al.  Minors and the right to consent to health care. , 2000, Issues in brief.

[11]  S. Hull,et al.  Variability among institutional review boards’ decisions within the context of a multicenter trial , 2001, Critical care medicine.

[12]  R. Wittes,et al.  A central institutional review board for multi-institutional trials. , 2002, The New England journal of medicine.

[13]  R. Califf,et al.  Monitoring and ensuring safety during clinical research. , 2001, JAMA.

[14]  H. Greely Human Genomics Research: New Challenges for Research Ethics , 2001, Perspectives in biology and medicine.

[15]  P. Reilly,et al.  Rethinking risks to human subjects in genetic research. , 1998, American journal of human genetics.

[16]  L Lasagna,et al.  Demystifying central review boards: current options and future directions. , 2000, IRB.

[17]  R. Reves,et al.  Breaking the Camel's Back: Multicenter Clinical Trials and Local Institutional Review Boards , 2001, Annals of Internal Medicine.

[18]  Mary L. Durham How Research Will Adapt to HIPAA: A View from Within the Healthcare Delivery System , 2002, American Journal of Law & Medicine.